Details of the Drug

General Information of Drug (ID: DMKA8J4)

Drug Name
Etonogestrel
Synonyms
Etonogestrelum; Implanon; Implanon (TN); NuvaRing (TN); Etonogestrel (USAN/INN); (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one; 17alpha-ethynyl-17beta-hydroxy-11-methylidene-18a-homo-estr-4-en-3-one; 3-Ketodesogestrel; 3-Oxodesogestrel
Indication
Disease Entry ICD 11 Status REF
Contraception QA21 Approved [1], [2]
Therapeutic Class
Contraceptive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 324.5
Topological Polar Surface Area (xlogp) 3.3
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability
76% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The clearance of drug is 7.5 L/h [5]
Elimination
0.1% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 25 hours [6]
Metabolism
The drug is metabolized via the liver [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.00805 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.02% [8]
Vd
The volume of distribution (Vd) of drug is 201 L [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.51 mg/mL [3]
Chemical Identifiers
Formula
C22H28O2
IUPAC Name
(8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
Canonical SMILES
CC[C@]12CC(=C)[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34
InChI
InChI=1S/C22H28O2/c1-4-21-13-14(3)20-17-9-7-16(23)12-15(17)6-8-18(20)19(21)10-11-22(21,24)5-2/h2,12,17-20,24H,3-4,6-11,13H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1
InChIKey
GCKFUYQCUCGESZ-BPIQYHPVSA-N
Cross-matching ID
PubChem CID
6917715
ChEBI ID
CHEBI:50777
CAS Number
54048-10-1
DrugBank ID
DB00294
TTD ID
D02KIU
INTEDE ID
DR0667

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Progesterone receptor (PGR) TTUV8G9 PRGR_HUMAN Binder [9], [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Contraception
ICD Disease Classification QA21
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Progesterone receptor (PGR) DTT PGR 3.26E-38 -3.79 -2.5
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 2.20E-02 -1.08E-01 -2.31E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Etonogestrel (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Metreleptin DM1NOEK Moderate Decreased metabolism of Etonogestrel caused by Metreleptin mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [28]
Pioglitazone DMKJ485 Minor Increased metabolism of Etonogestrel caused by Pioglitazone mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [29]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Etonogestrel caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [30]
Arn-509 DMT81LZ Moderate Increased metabolism of Etonogestrel caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [31]
Emapalumab DMZG5WL Moderate Altered metabolism of Etonogestrel due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [32]
Mitotane DMU1GX0 Moderate Increased metabolism of Etonogestrel caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [31]
Siltuximab DMGEATB Moderate Altered metabolism of Etonogestrel due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [32]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Etonogestrel caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [33]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Etonogestrel caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [34]
Clobazam - Lundbeck DMW1OQ0 Moderate Increased metabolism of Etonogestrel caused by Clobazam - Lundbeck mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [35]
Voriconazole DMAOL2S Moderate Decreased metabolism of Etonogestrel caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [36]
Posaconazole DMUL5EW Moderate Decreased metabolism of Etonogestrel caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [36]
Aminophylline DML2NIB Moderate Decreased metabolism of Etonogestrel caused by Aminophylline. Asthma [CA23] [37]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Etonogestrel caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [38]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Etonogestrel caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [39]
Ag-221 DMS0ZBI Moderate Increased metabolism of Etonogestrel caused by Ag-221 mediated induction of CYP450 enzyme. BCR-ABL1-negative chronic myeloid leukaemia [2A41] [40]
Pexidartinib DMS2J0Z Major Increased metabolism of Etonogestrel caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [41]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Etonogestrel caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [42]
Tucatinib DMBESUA Moderate Decreased metabolism of Etonogestrel caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [43]
Atorvastatin DMF28YC Minor Decreased metabolism of Etonogestrel caused by Atorvastatin mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [44]
Secobarbital DM14RF5 Moderate Increased metabolism of Etonogestrel caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [31]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Etonogestrel caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [35]
Oxtriphylline DMLHSE3 Moderate Decreased metabolism of Etonogestrel caused by Oxtriphylline. Cough [MD12] [37]
Aminoglutethimide DMWFHMZ Moderate Increased metabolism of Etonogestrel caused by Aminoglutethimide mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [31]
Lumacaftor DMCLWDJ Major Increased metabolism of Etonogestrel caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [32]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Etonogestrel caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [45]
MK-8228 DMOB58Q Moderate Decreased metabolism of Etonogestrel caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [38]
Aprepitant DM053KT Moderate Increased metabolism of Etonogestrel caused by Aprepitant mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [35]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Etonogestrel caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [46]
Griseofulvin DMK54YG Major Increased metabolism of Etonogestrel caused by Griseofulvin mediated induction of CYP450 enzyme. Dermatophytosis [1F28] [47]
Primidone DM0WX6I Major Increased metabolism of Etonogestrel caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [31]
Felbamate DM1V5ZS Major Increased metabolism of Etonogestrel caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [31]
Oxcarbazepine DM5PU6O Major Increased metabolism of Etonogestrel caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [31]
Cenobamate DMGOVHA Moderate Increased metabolism of Etonogestrel caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [31]
Stiripentol DMMSDOY Moderate Decreased metabolism of Etonogestrel caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [48]
Fosphenytoin DMOX3LB Major Increased metabolism of Etonogestrel caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [31]
Brivaracetam DMSEPK8 Minor Increased metabolism of Etonogestrel caused by Brivaracetam mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [32]
Rufinamide DMWE60C Moderate Increased metabolism of Etonogestrel caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [38]
Phenobarbital DMXZOCG Major Increased metabolism of Etonogestrel caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [31]
Carbamazepine DMZOLBI Major Increased metabolism of Etonogestrel caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [31]
Eslicarbazepine DMZREFQ Major Increased metabolism of Etonogestrel caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [31]
Tazemetostat DMWP1BH Moderate Increased metabolism of Etonogestrel caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [49]
Itraconazole DMCR1MV Moderate Decreased metabolism of Etonogestrel caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [36]
Miconazole DMPMYE8 Moderate Decreased metabolism of Etonogestrel caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [36]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Etonogestrel caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [36]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Etonogestrel caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [31]
Boceprevir DMBSHMF Major Increased metabolism of Etonogestrel caused by Boceprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [35]
Telaprevir DMMRV29 Major Increased metabolism of Etonogestrel caused by Telaprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [35]
Rifampin DMA8J1G Major Increased metabolism of Etonogestrel caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [50]
Rifapentine DMCHV4I Major Increased metabolism of Etonogestrel caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [51]
Efavirenz DMC0GSJ Moderate Increased metabolism of Etonogestrel caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [32]
Saquinavir DMG814N Moderate Decreased metabolism of Etonogestrel caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [52]
Darunavir DMN3GCH Moderate Decreased metabolism of Etonogestrel caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [53]
Atazanavir DMSYRBX Moderate Decreased metabolism of Etonogestrel caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [54]
Conivaptan DM1V329 Moderate Decreased metabolism of Etonogestrel caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [55]
Lesinurad DMUR64T Moderate Increased metabolism of Etonogestrel caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [56]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Etonogestrel caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [57]
Amobarbital DM0GQ8N Moderate Increased metabolism of Etonogestrel caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [31]
Pentobarbital DMFNH7L Moderate Increased metabolism of Etonogestrel caused by Pentobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [31]
Linaclotide DM4EGV0 Moderate Altered absorption of Etonogestrel caused by Linaclotide. Irritable bowel syndrome [DD91] [32]
Glycerol phenylbutyrate DMDGRQO Moderate Increased metabolism of Etonogestrel caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme. Liver disease [DB90-DB9Z] [32]
Brigatinib DM7W94S Major Increased metabolism of Etonogestrel caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [58]
PF-06463922 DMKM7EW Moderate Increased metabolism of Etonogestrel caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [31]
Selpercatinib DMZR15V Moderate Decreased metabolism of Etonogestrel caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [32]
Artemether DM48QOT Moderate Increased metabolism of Etonogestrel caused by Artemether mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [59]
IPI-145 DMWA24P Moderate Decreased metabolism of Etonogestrel caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [60]
Vemurafenib DM62UG5 Moderate Increased metabolism of Etonogestrel caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [31]
LGX818 DMNQXV8 Major Increased metabolism of Etonogestrel caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [61]
Dabrafenib DMX6OE3 Major Increased metabolism of Etonogestrel caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [35]
Exjade DMHPRWG Moderate Increased metabolism of Etonogestrel caused by Exjade mediated induction of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [62]
Carfilzomib DM48K0X Major Additive thrombogenic effects by the combination of Etonogestrel and Carfilzomib. Multiple myeloma [2A83] [32]
Rifabutin DM1YBHK Major Increased metabolism of Etonogestrel caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [51]
Bexarotene DMOBIKY Major Increased metabolism of Etonogestrel caused by Bexarotene mediated induction of CYP450 enzyme. Mycosis fungoides [2B01] [35]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Etonogestrel caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [32]
Nilotinib DM7HXWT Moderate Decreased metabolism of Etonogestrel caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [63]
Dasatinib DMJV2EK Moderate Decreased metabolism of Etonogestrel caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [64]
Modafinil DMYILBE Moderate Increased metabolism of Etonogestrel caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [38]
E-2007 DMJDYNQ Moderate Increased metabolism of Etonogestrel caused by E-2007 mediated induction of CYP450 enzyme. Neuropathy [8C0Z] [38]
Olaparib DM8QB1D Moderate Increased metabolism of Etonogestrel caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [32]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Etonogestrel caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [65]
Abametapir DM2RX0I Moderate Decreased metabolism of Etonogestrel caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [66]
Lefamulin DME6G97 Moderate Decreased metabolism of Etonogestrel caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [67]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Etonogestrel caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [68]
Enzalutamide DMGL19D Moderate Increased metabolism of Etonogestrel caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [31]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Etonogestrel due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [32]
Ixekizumab DMXW92T Moderate Altered metabolism of Etonogestrel due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [32]
Bosentan DMIOGBU Major Increased metabolism of Etonogestrel caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [35]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Etonogestrel and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [69]
Tocilizumab DM7J6OR Moderate Altered metabolism of Etonogestrel due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [32]
Canakinumab DM8HLO5 Moderate Altered metabolism of Etonogestrel due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [32]
Rilonacept DMGLUQS Moderate Altered metabolism of Etonogestrel due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [32]
Golimumab DMHZV7X Moderate Altered metabolism of Etonogestrel due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [32]
Nafcillin DMN9RPO Moderate Increased metabolism of Etonogestrel caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [31]
Sarilumab DMOGNXY Moderate Altered metabolism of Etonogestrel due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [32]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Etonogestrel caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [70]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Etonogestrel caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [32]
Larotrectinib DM26CQR Moderate Decreased metabolism of Etonogestrel caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [38]
Armodafinil DMGB035 Moderate Increased metabolism of Etonogestrel caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [38]
Pitolisant DM8RFNJ Moderate Increased metabolism of Etonogestrel caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [32]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Etonogestrel caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [71]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Etonogestrel and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [69]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Etonogestrel and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [69]
Elagolix DMB2C0E Moderate Increased metabolism of Etonogestrel caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [31]
⏷ Show the Full List of 103 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7590).
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Wenzl R, van Beek A, Schnabel P, Huber J: Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon. Contraception. 1998 Nov;58(5):283-8.
6 PMC
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
9 Pharmacological profile of progestins. Maturitas. 2008 Sep-Oct;61(1-2):151-7.
10 Endometrial effects of etonogestrel (Implanon) contraceptive implant. Curr Opin Obstet Gynecol. 2001 Jun;13(3):335-41.
11 The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel. Br J Clin Pharmacol. 2005 Jul;60(1):69-75.
12 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21 Clinical pipeline report, company report or official report of lipocine.
22 Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids. 2000 Oct-Nov;65(10-11):733-40.
23 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
24 Focus on anastrozole and breast cancer. Curr Med Res Opin. 2003;19(8):683-8.
25 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
26 Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharm... Steroids. 2008 Feb;73(2):222-31.
27 Contribution of functional groups of 19-nor-progestogens to binding to progesterone and estradiol-17beta receptors in rabbit uterus. Endocrinology. 1977 Jun;100(6):1579-84.
28 Product Information. Myalept (metreleptin). Bristol-Myers Squibb, Princeton, NJ.
29 Glazer NB, Cheatham WW "Thiazolidinediones for type 2 diabetes - No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4." Br Med J 322 (2001): 235-6. [PMID: 11159615]
30 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
31 Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
32 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
33 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
34 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
35 Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.".
36 Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9. [PMID: 2547410]
37 Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski R "Effects of tobacco smoking and oral contraceptive use on theophylline disposition." Br J Clin Pharmacol 16 (1983): 271-80. [PMID: 6626419]
38 Cerner Multum, Inc. "Australian Product Information.".
39 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
40 Product Information. Idhifa (enasidenib). Celgene Corporation, Summit, NJ.
41 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
42 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
43 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
44 Product Information. Lipitor (atorvastatin). Parke-Davis, Morris Plains, NJ.
45 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
46 Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
47 Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM "Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics." Br J Clin Pharmacol 25 (1988): 527-32. [PMID: 3408633]
48 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
49 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
50 Back DJ, Breckenridge AM, Crawford F, et al. "The effect of rifampicin on norethisterone pharmacokinetics." Eur J Clin Pharmacol 15 (1979): 193-7. [PMID: 37091]
51 Archer JS, Archer DF "Oral contraceptive efficacy and antibiotic interaction: A myth debunked." J Am Acad Dermatol 46 (2002): 917-23. [PMID: 12063491]
52 Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
53 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
54 Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
55 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
56 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
57 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
58 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
59 Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.".
60 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
61 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
62 Product Information. Desferal (deferoxamine). Novartis Pharmaceuticals, East Hanover, NJ.
63 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
64 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
65 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
66 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
67 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
68 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
69 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
70 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
71 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.